$1.040
+0.042 (+4.00%)Zum Schluss
CVKD-News
CVKD-Events
Cadrenal Therapeutics Initiates Strategic Review to Maximize Company Value
Cadrenal Therapeutics announced that its board of directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its asset portfolio. The initiative builds on Cadrenal's ongoing strategic partnering discussions and will evaluate a broad range of potential transactions involving the company and its clinical- and development-stage programs, including CAD-1005, tecarfarin, frunexian, and CAD-2000, the company's second-generation 12-LOX platform. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, or other strategic transactions. Cadrenal has engaged Tungsten Advisors as the company's exclusive strategic financial advisor in connection with the process.
Cadrenal Therapeutics Aligns on CAD-1005 Trial Protocol with FDA
Cadrenal Therapeutics announced feedback from a Type D Meeting with the FDA held on July 28. During the meeting, Cadrenal and the FDA aligned on aspects of the protocol and Statistical Analysis Plan for the Phase 3 registrational study of CAD-1005, the company's 12-lipoxygenase inhibitor in development to treat heparin-induced thrombocytopenia. During the Type D meeting, the FDA agreed on an optimized definition of worsening HIT for the primary endpoint, based on progression of thrombotic events through Day 14 of treatment or hospital discharge. The updated composite primary endpoint will measure the proportion of Serotonin Release Assay-positive participants with adjudicated new or worsening composite thromboembolic events through Day 14 or hospital discharge. Additionally, the FDA agreed to use placebo control in the Phase 3 trial, with standard anticoagulation therapeutics for both the CAD-1005 and placebo control arms.
Cadrenal Therapeutics Files to Sell 2.94M Shares of Common Stock
Cadrenal Therapeutics files to sell 2.94M shares of common stock for holders
Cadrenal Therapeutics CAD-1005 Clinical Data Significantly Improves Thrombotic Events
Cadrenal Therapeutics announced that late-breaking clinical data from the Phase 2 study of the 12-lipoxygenase inhibitor CAD-1005 were featured in a highly anticipated late-breaking oral presentation at the International Society on Thrombosis and Haemostasis 2026 Congress in Paris. Unlike standard-of-care anticoagulants that only reduce thrombin generation, CAD-1005 is designed to directly block the underlying 12-LOX immune signaling loop that drives antibody-mediated platelet activation. Patients treated with CAD-1005 experienced a reduction of more than 25% in new or worsening thrombotic events compared with the placebo arm, despite the study not being sufficiently powered for statistical significance. No serious adverse events attributable to CAD-1005, no major bleeding in SRA+ patients, and no deaths. Treatment with CAD-1005 was associated with fewer thromboembolic events without an increase in major bleeding. The trial established that the traditional platelet count recovery rate is an inadequate surrogate for clinical efficacy, as thrombotic events continued to occur after recovery.
Cadrenal Therapeutics Submits Rare Pediatric Disease Application
Cadrenal Therapeutics announced plans to submit a Rare Pediatric Disease Designation, RPDD, request to the U.S. Food and Drug Administration, FDA, for tecarfarin as a treatment for pediatric patients with Kawasaki disease who develop coronary artery aneurysms, CAAs, and require chronic oral anticoagulation. The announcement comes ahead of the BIO International Convention, June 22-25, 2026, in San Diego, California. Cardenal's executive leadership team will highlight this rare pediatric initiative and its Phase 3-ready CAD-1005 platform during one-on-one partnering meetings with global and regional pharmaceutical companies.
Ähnliche Artikel
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.